The U.S. Supreme Court has denied the petition for a writ of certiorari (orders a lower court to deliver its record in a case so the higher court may review it) from a subsidiary of Hikma Pharmaceuticals related to U.S. Patent No. 8,586,610 covering Vanda Pharmaceuticals’ (VNDA -5.2%) Fanapt (iloperidone) tablets.
The denial means that the patent will remain in effect through November 2, 2027 (unless successfully challenged beforehand).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.